Dysregulated CD38 Expression on Peripheral Blood Immune Cell Subsets in SLE

• DOI: 10.3390/ijms22052424
• Publication Date: 2021-03-01T01:43:32Z
• Authors: Marie Burns; Lennard Ostendorf; Robert Biesen; Andreas Grützkau; Falk Hiepe; Henrik E. Mei; Tobias Alexander
• Keywords: CD16

Given its uniformly high expression on plasma cells, CD38 has been considered as a therapeutic target in patients with systemic lupus erythematosus (SLE). Herein, we investigate the distribution of by peripheral blood leukocyte lineages to evaluate potential effect CD38-targeting antibodies these immune cell subsets and delineate use biomarker SLE. We analyzed flow mass cytometry two different cohorts, comprising total 56 SLE patients. The levels were subsequently correlated across subsets, clinical serologic disease parameters Compared healthy controls (HC), significantly increased circulating plasmacytoid dendritic CD14++CD16+ monocytes, CD56+ CD16dim natural killer marginal zone-like IgD+CD27+ B CD4+ CD8+ memory T cells. Correlation analyses revealed coordinated between individual innate but not HC. However, heterogeneous patients, no correlation was found activity index SLEDAI-2K or established immunological markers activity. In conclusion, identified widespread changes cells that highly over within heterogenous population regardless severity manifestations. As anti-CD38 treatment is being investigated SLE, our results may have important implications for personalized targeting pathogenic leukocytes monoclonal antibodies.